Remove 2025 Remove Pharmacokinetics Remove Treatment
article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

Earlier in her career, she held several leadership roles within AstraZeneca, including Senior Director for Drug Metabolism & Pharmacokinetics and Director for Lead Optimisation & Enabling Technologies within medicinal chemistry.

RNA 59
article thumbnail

Novo Nordisk: Phase 3 Data Shows Mim8 Well-Tolerated After Switch from Emicizumab in Hemophilia A

The Pharma Data

The study marks a significant step forward in the treatment landscape for haemophilia A, demonstrating not only clinical safety and pharmacokinetic stability, but also strong patient preference for the Mim8 pen-injector delivery system. Throughout the 26-week study period, the investigational therapy was well-tolerated.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen Unveils Phase 2 Obesity Trial Results for Monthly Maritide at ADA’s 85th Scientific Sessions

The Pharma Data

In tandem with the Phase 2 results, Amgen also shared detailed data from its Phase 1 Pharmacokinetics Low Dose Initiation (PK-LDI) study. This study explored the effects of beginning treatment with lower starting doses of MariTide to improve tolerability while maintaining clinical benefit.

Trials 40
article thumbnail

A spatial approach to understanding drug dynamics using mass spectrometry imaging

Drug Target Review

Unlike traditional pharmacokinetic (PK) studies that rely on plasma measurements alone, MSI, when combined with traditional histology, enables spatial mapping of drug distribution, metabolism and target engagement. Drug Discovery Today 2025, 30 (1), 104275. Mass Spectrometry Imaging for Spatially Resolved Multi-Omics Molecular Mapping.

Drugs 52
article thumbnail

BeOne Medicines Gains CHMP Backing for BRUKINSA Tablet Formulation

The Pharma Data

A Patient-Centered Innovation in B-Cell Cancer Treatment Zanubrutinib, marketed as BRUKINSA, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of various B-cell malignancies.

article thumbnail

FDA Approves Tablet Form of BeOne’s BRUKINSA® for All Indications

The Pharma Data

This decision represents a pivotal moment in the evolution of treatment convenience for patients with certain B-cell malignancies, while reinforcing BRUKINSA’s stronghold in the BTK inhibitor market. The agency has officially approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five of its previously approved indications.

article thumbnail

Amgen to Present Phase 2 Maritide Data at ADA 85th Scientific Sessions

The Pharma Data

Unlike traditional peptide-only approaches, its antibody-based design may enhance durability, extend dosing intervals, and potentially reduce tolerability-related treatment discontinuations. At ADA 2025, the company aims to deepen the clinical narrative by sharing more comprehensive and peer-reviewed data.